國立高雄大學圖資館 |

Language: English

Back

Anti-angiogenic therapy in ophthalmology

SpringerLink (Online service)

Anti-angiogenic therapy in ophthalmology

Record Type:	Electronic resources : Monograph/item
Title/Author:	Anti-angiogenic therapy in ophthalmologyedited by Andreas Stahl.
other author:	Stahl, Andreas.
Published:	Cham :Springer International Publishing :2016.
Description:	x, 193 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
Subject:	EyeDiseases
Online resource:	http://dx.doi.org/10.1007/978-3-319-24097-8
ISBN:	9783319240978$q(electronic bk.)

Anti-angiogenic therapy in ophthalmology
Anti-angiogenic therapy in ophthalmology[electronic resource] /edited by Andreas Stahl. - Cham :Springer International Publishing :2016. - x, 193 p. :ill. (some col.), digital ;24 cm. - Essentials in ophthalmology,1612-3212. - Essentials in ophthalmology..

Retinal Vascular Development -- Retinopathy of Prematurity -- Anti-Vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors -- AREDS Supplementation and the Progression Towards Neovascular Exudative AMD -- VEGF-Inhibition in Macular Telangiectasia Type 2 -- Diabetic Retinopathy -- Retinal Vein Occlusion -- Pharmacokinetics of Intravitreally Applied VEGF Inhibitors -- Neovascular Glaucoma -- Corneal Neovascular Diseases -- Anti-Angiogenic Gene Therapy - Basic Science and Challenges for Translation into the Clinic.

This book provides a concise overview over the pathology of retinal angiogenic diseases and explains why anti-angiogenic therapy is effective in so many patients. The reader is guided through the various clinical indications for anti-angiogenic therapy and made aware of its merits as well as current challenges and limitations. It is explained how, since its introduction for the treatment of exudative age-related macular degeneration in 2006, anti-angiogenic therapy has revolutionized the way in which we treat a range of ocular diseases. All of the authors are established experts in their respective fields who share their extensive knowledge and clinical experience with the reader. This book is both a valuable introduction to anti-angiogenic therapy in ophthalmology and a day-to-day companion for all ophthalmologists seeing patients with some of the most prevalent retinal diseases.

ISBN: 9783319240978$q(electronic bk.)

Standard No.: 10.1007/978-3-319-24097-8doiSubjects--Topical Terms:

317984
Eye
--Diseases

LC Class. No.: RE48

Dewey Class. No.: 617.706

Anti-angiogenic therapy in ophthalmology
LDR:02457nmm a2200325 a 4500 001 489448
003 DE-He213
005 20161024152512.0
006 m d
007 cr nn 008maaau
008 161213s2016 gw s 0 eng d
020 $a 9783319240978$q(electronic bk.)
020 $a 9783319240954$q(paper)
024 7 $a 10.1007/978-3-319-24097-8 $2 doi
035 $a 978-3-319-24097-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RE48
072 7 $a MJQ $2 bicssc
072 7 $a MED063000 $2 bisacsh
082 0 4 $a 617.706 $2 23
090 $a RE48 $b .A629 2016
245 0 0 $a Anti-angiogenic therapy in ophthalmology $h [electronic resource] / $c edited by Andreas Stahl.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a x, 193 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Essentials in ophthalmology, $x 1612-3212
505 0 $a Retinal Vascular Development -- Retinopathy of Prematurity -- Anti-Vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors -- AREDS Supplementation and the Progression Towards Neovascular Exudative AMD -- VEGF-Inhibition in Macular Telangiectasia Type 2 -- Diabetic Retinopathy -- Retinal Vein Occlusion -- Pharmacokinetics of Intravitreally Applied VEGF Inhibitors -- Neovascular Glaucoma -- Corneal Neovascular Diseases -- Anti-Angiogenic Gene Therapy - Basic Science and Challenges for Translation into the Clinic.
520 $a This book provides a concise overview over the pathology of retinal angiogenic diseases and explains why anti-angiogenic therapy is effective in so many patients. The reader is guided through the various clinical indications for anti-angiogenic therapy and made aware of its merits as well as current challenges and limitations. It is explained how, since its introduction for the treatment of exudative age-related macular degeneration in 2006, anti-angiogenic therapy has revolutionized the way in which we treat a range of ocular diseases. All of the authors are established experts in their respective fields who share their extensive knowledge and clinical experience with the reader. This book is both a valuable introduction to anti-angiogenic therapy in ophthalmology and a day-to-day companion for all ophthalmologists seeing patients with some of the most prevalent retinal diseases.
650 0 $a Eye $x Diseases $x Treatment. $3 317984
650 0 $a Ophthalmology. $3 274149
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Angiology. $3 275861
700 1 $a Stahl, Andreas. $3 747952
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Essentials in ophthalmology. $3 678200
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-24097-8
950 $a Medicine (Springer-11650)